Trial Profile
Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2011 Results published in Clinical and Vaccine Immunology.
- 04 Nov 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Oct 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.